logo
Plus   Neg
Share
Email

Novartis To Begin Making Potential Coronavirus Vaccine

Novartis's gene-therapy arm AveXis will begin manufacturing a gene-based coronavirus vaccine this month. The vaccine being developed by scientists at Massachusetts Eye and Ear hospital, Massachusetts General and the University of Pennsylvania.

As per a deal with Massachusetts researchers, AveXis will contributing its technology, expertise and supply chain at no cost to supply the AAV vaccine for COVID clinical trials scheduled to begin in the second half of 2020.

".....we are pleased to lend our unparalleled manufacturing expertise, technology and supply chain to produce a COVID vaccine for use in clinical trials.," said Dave Lennon, president of AveXis.

No vaccine has been proven effective against Covid-19, the illness caused by the novel coronavirus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT